Information Letter on SGLT2 inhibitors: Risk of diabetic ketoacidosis
2015.07.10
Active substance: canagliflozin, capagliflozin, empagliflozin
The companies AstraZeneca AB, Boehringer Ingelheim International GmbH and Janssen-Cilag International N.V. are circulating information on the risk of diabetic ketoacidosis under treatment with SGLT2 inhibitors.
Details on the procedure can be found on the website of the European Medicines Agency (EMA):
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN